Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial

Kaiyang Ding,[1*] Hailing Liu,[2*] Jie Ma,[3*] Haiyan Yang,[4] Lei Cao,[2] Huihan Wang,[5] Hongling Peng,[6] Wei Shi,[7] Xiaoli Zhao,[2] Wei Wu,[2] Huayuan Zhu,[2] Jianyong Li[2] and Lei Fan[2]

[1]Department of Hematology, Anhui Provincial Hospital, the First Affiliated Hospital of USTC, Hefei, Anhui; [2]Department of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, Jiangsu; [3]Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan; [4]Department of Lymphoma, Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang; [5]Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, Liaoning; [6]Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan and [7]Department of Hematology, the Friendship Hospital of Ili Kazakh Autonomous Prefecture, Yining, Xinjiang, China.

**KD, HL, and JM contributed equally as first authors.*

Correspondence:
L. Fan
fanlei3014@126.com

J. Li
lijianyonglm@126.com

Received: October 13, 2022.
Accepted: January 19, 2023.
Early view: January 26, 2023.

https://doi.org/10.3324/haematol.2022.282266

Supplementary Table 1. Inclusion and exclusion criteria

Inclusion Criteria	1. A diagnosis of classic Hodgkin lymphoma as per World Health Organisation classification criteria; 2. At least one prior treatment regimen; 3. Evidence of relapsed or refractory disease; 4. Eastern Cooperative Oncology Group performance status 0 to 2; 5. At least one measurable lesion; 6. A life expectancy of at least 3 months; 7. Adequate organ functions.
Exclusion Criteria	1. Medical histories and complications are as follows: 1) Confirmed central nervous system involvement; 2) Active autoimmune disease; 3) Known interstitial pneumonia; 4) Uncontrolled coronary artery disease or arrhythmia; 5) Myocardial infarction within 6 months; 6) New York Heart Association Class III or IV congestive heart failure; 7) Other active malignancies requiring treating; 8) Severe infection requiring systemic therapy; 9) Known human immunodeficiency virus positive or acquired immunodeficiency syndrome; 10) Active hepatitis included patients with active hepatitis B virus infection and active hepatitis C virus infection; 11) Received anti-tumor vaccines or other anti-tumor therapy with immune stimulation within 3 months; 2. Participating in another trial; 3. Pregnant or lactating women; 4. Known allergy to the ingredients of the test drug; 5. Other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subject safety or test data and sample collection.

Supplementary Table 2. Immune-related adverse events

Term	All grades	Grade 1	Grade 2	Grade 3
	***n* (%)**	***n* (%)**	***n* (%)**	***n* (%)**
Hypothyroidism	9 (30.0)	6 (20.0)	3 (10.0)	0
Rash	4 (13.3)	1 (3.3)	3 (10.0)	0
Elevated transaminase	3 (10.0)	2 (6.7)	0	1 (3.3)
Hyperthyroidism	2 (6.7)	2 (6.7)	0	0
Cardiac toxicity †	1 (3.3)	1 (3.3)	0	0

† ventricular arrhythmias of unknown origin.